Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biodesix (BDSX) Other Non-Current Liabilities: 2019-2025

Historic Other Non-Current Liabilities for Biodesix (BDSX) over the last 5 years, with Sep 2025 value amounting to $769,000.

  • Biodesix's Other Non-Current Liabilities rose 24.03% to $769,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $769,000, marking a year-over-year increase of 24.03%. This contributed to the annual value of $815,000 for FY2024, which is 14.47% up from last year.
  • Per Biodesix's latest filing, its Other Non-Current Liabilities stood at $769,000 for Q3 2025, which was up 40.07% from $549,000 recorded in Q2 2025.
  • Biodesix's Other Non-Current Liabilities' 5-year high stood at $30.9 million during Q1 2021, with a 5-year trough of $549,000 in Q2 2025.
  • Its 3-year average for Other Non-Current Liabilities is $3.6 million, with a median of $744,000 in 2024.
  • Per our database at Business Quant, Biodesix's Other Non-Current Liabilities spiked by 34.08% in 2023 and then crashed by 96.24% in 2024.
  • Biodesix's Other Non-Current Liabilities (Quarterly) stood at $16.0 million in 2021, then grew by 16.33% to $18.6 million in 2022, then plummeted by 96.18% to $712,000 in 2023, then increased by 14.47% to $815,000 in 2024, then climbed by 24.03% to $769,000 in 2025.
  • Its last three reported values are $769,000 in Q3 2025, $549,000 for Q2 2025, and $692,000 during Q1 2025.